297 results about "Cellular viability" patented technology

A method of determining information about cell viability and other characteristics relating to cell membrane permeability is disclosed. The method involves determining the effect of a cell on current flow and relating that effect to a known standard which standard may be a known healthy cell and thereby deducing the viability of the cell being tested. The cells being tested can be subjected to different environmental conditions such as surrounding chemicals, temperature, pH and pressure to determine the effects of such conditions on cell viability and/or cell permeability. The cell being tested can be in a cell suspension, grown on s ubstarte, in tissue in vitro or in tissue in vivo. The method provides substantially instantaneous results and need not include the use of dyes or other markers.

This invention comprises administering to a human or animal in need of treatment an effective amount of an antioxidant lipoic acid derivative and/or pharmaceutically acceptable salts and solvates thereof for the treatment or prevention of pathological (inflammatory, proliferative and degenerative diseases, e.g. diabetes mellitus, atherosclerosis, Alzheimer's disease and chronic viral diseases) and non-pathological (e.g. skin aging and wrinkle formation) conditions caused by oxidative damage. Methods of synthesizing novel antioxidant lipoic acid derivatives and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are described. Another aspect of this invention is the use of these antioxidant compositions for the protection of skin from damage caused by ultraviolet radiation and dessication, and to provide improved skin feel by desquamating, cleansing and clarifying the skin. The compositions described in this invention increase cellular viability of epidermal cells, promote cytoprotection, and decrease the production of inflammatory mediators such as inflammatory cytokines in these cells. The antioxidant compositions are incorporated into sunscreen products, soap, moisturizing lotions, skin toners, and other skin care products.

The present invention is directed to nanoparticle compositions for maintaining organ, tissue and cellular viability when such are separated from normal physiological supports. Compositions containing the nanoparticle compositions and methods of preserving organs such as kidneys, both in vivo and ex vivo, are also disclosed.

Compositions comprising hydroxytyrosol-containing formulations and treatment regiments comprising hydroxytyrosol and/or oleuropein and chemotherapeutic agents are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for treating or preventing high glucose-induced dysfunction, treating or preventing chemotherapy-induced dysfunction, and for improving cell viability are provided. Various methods for use of the hydroxytyrosol compositions for inhibition of lysine specific demethylase 1 (LSD1) in various cancers are also provided.

A method of analyzing bubbles, cells, cell viability, or other particles or agglomerates in a process liquid contained in a vessel is provided. Images of bubbles, cells or other particles in the liquid are obtained in-situ with a vision probe extending through a wall of the vessel. The images are analyzed with image recognition software. The software measures at lease one of bubble, cell or particle size, mean diameter, surface area, flow rate, flow pattern, population distribution, viability, agglomerates or clumping, color change, viscosity, Sauter mean, ratio of surface area of bubbles relative to volume of bubbles, gas hold-up ratio of gas volume to volume of liquid, or interfacial area. The software distinguishes valid or viable bubbles, cells or particles that should be included in an analysis from invalid or non-viable bubbles, cells or particles that should not be included. The software can be configured to provide an analysis of the valid bubbles, cells or particles that fall within pre-set size and shape or viability parameters.

The present invention relates to a novel selection system for use in a eukaryotic cell culture process and for expression of a recombinant product of interest. The selection system is based on the introduction of an exogenous functional membrane-bound folate receptor gene together with the polynucleotide or gene encoding the product of interest into a eukaryotic cell and can be widely utilized with eukaryotic cells for which cellular viability is dependent upon folic acid uptake.

A novel electrically conductive polymer composite composed of polycaprolactone fumarate-polypyrrole (PCLF-PPy) for applications in nerve regeneration is disclosed. The synthesis and characterization of PCLF-PPy and in vitro studies showing PCLF-PPy supports both PC12 cell and Dorsal Root Ganglia neurite extension. PCLF-PPy composite materials were synthesized by polymerizing pyrrole in pre-formed scaffolds of PCLF resulting in an interpenetrating network of PCLF-PPy. PCLF-PPy composite materials possess electrical conductivity up to 6 mS cm⁻¹ with compositions ranging from 5-13.5 percent polypyrrole of the bulk material. Surface topographies of PCLF-PPy materials show microstructures with a RMS roughness of 1195 nm and nanostructures with RMS roughness of 8 nm. PCLF-PPy derivatives were synthesized with anionic dopants to determine effects on electrical conductivity and to optimize the chemical composition for biocompatibility. In vitro studies using PC12 show PCLF-PPy composite materials induce a higher cellular viability and increased neurite extension compared to PCLF. PCLF-PPy composites doped with either naphthalene sulfonic acid or dodecyl benzene sulfonic acid are determined to be the optimal materials for electrical stimulation. In vitro studies showed significant increases in percentage of neurite bearing cells, number of neurites per cell and neurite length in the presence of ES compared to no ES. Additionally, extending neurites were observed to align in the direction of the applied current. Electrically conductive PCLF-PPy scaffolds possess material properties necessary for application as nerve conduits. Additionally, the capability to significantly enhance and direct neurite extension by passing electrical current through PCLF-PPy scaffolds renders them even more promising as future therapeutic treatments for severe nerve injuries.

The biological functionality of living microbial spores is modified using phenotypic engineering to endow the resulting modified spores with novel functionality that extends the usefulness of the spores for a variety of practical applications including, for example, sterility testing, the release of active compounds, and cell-based biosensing systems. A preferred embodiment entails engineering Bacillus spores to acquire synthetic new functions that enable the modified spores to sense and rapidly transduce specific germination signals in their surroundings. The newly acquired functions allow the spores to perform, for example, as self-reporters of cellular viability, self-indicating components of cell-based biosensors, and in other analytical systems.

The invention provides a method for in vitro induction and amplification of a human antigen nonspecific regulatory T cell. A human peripheral blood CD4<+> T cell with an abundant source is separated, and a CD4<+>CD25<-> T cell is induced and amplified into a CD4<+>CD25<+>CD127<dim> antigen nonspecific regulatory T cell with high purity and high regulation efficiency within a short period through a simple induction method meeting the Clinical Good Manufacturing Practice (GMP). An enough therapeutic dose of Treg can be obtained through induced cultivation of a week (6-7d), the phenotype and regulation function of the induced Treg are stable, furthermore, the incidence rate of events, such as cell activity reduction and microbial contamination due to long-term culture in vitro is greatly reduced, and the quality control method is specific and fast and is very suitable for clinical application.

The present invention discloses a method of isolation, pooling and further culturing of Mesenchymal Stem cells (MSC) for clinical application. Present invention also discloses the method of establishing Master Cell bank, followed by Working Cell Bank from which the final therapeutic composition referred to as Investigational Product/Investigational Medicinal Product comprising of allogenic bone marrow-derived MSC is formulated for clinical applications. Present disclosure also discloses a robust manufacturing process for consistent production of clinical grade Mesenchymal Stromal cells (MSCs). The process enables production of highly viable potent cells. The process steps relating to preparation of media, cell seeding, harvesting are fine tuned to achieve consistency in cell yield, superior cell viability, purity, improved cell proliferation, high cell recovery, low HLA-DR expression, reduction in culture duration. The viability and purity of cells are further improved by optimized wash process without cell loss/cell stress. The disclosure further provides a method of cyrostoring MSCs at high cell density without affecting the viability of cells. It further provides economical means to store and transport at −80° C.

The invention discloses a separation method of human peripheral blood mononuclear cells. The separation method combines the advantages of a hydroxyethyl starch precipitation method and a Ficoll density gradient centrifugation method. The PBMC with a purity of greater than 95% and a vitality of greater than 85% is obtained by removing most of red blood cells by the hydroxyethyl starch precipitation method, then naturally settling in air, and then further purifying the mononuclear cells by the Ficoll density gradient centrifugation method, aiming at the separation characteristic of a high-capacity blood sample. Compared with a method without natural setting in air, the vitality and the purity of the cells obtained by the separation method are higher.

When a mutation, designated rad51M1, was generated in the mouse MmRAD51 gene, mutant embryos died shortly after implantation. rad51M1 cells exhibited hypersensitivity to ionizing radiation, reduced proliferation, programmed cell death and chromosome loss. The disruption of MmRad51 rotein-protein interactions stopped cell proliferation and/or reduced cell viability. Several proteins that interact with MmRad51 have been identified including, for example Brca2 and M96. Additionally, Rad51 self-associates via the N-terminal region. When a single residue was changed from a conserved lysine to an alanine, the alteration proved toxic to cells. Moreover, a rad51 allele that lacked the RecA homology region was also deleterious to cells. In view of the above, it is clear that inhibiting MmRad51 function or the function of any molecule that associates with MmRad51, or any molecule in the Rad51 or Rad52 pathways, hinders cell proliferation and/or viability. Accordingly, molecules capable of blocking these critical DNA repair pathways may be effective as therapeutics for inhibiting cell proliferation.